R&F Capital Advisors’s Gilead Sciences GILD Stock Holding History

R&F Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-23,851	Closed	-$1.71M	–	737
2016 Q4	$1.71M	Buy	+23,851	New	+$1.77M	0.6%	28

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

R&F Capital Advisors's GILD Position: Q1 2017 in Review

R&F Capital Advisors sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 23,851 shares — an estimated $1.71M sold.

R&F Capital Advisors first reported a position in GILD in Q4 2016 and held it in 1 quarter. The position peaked at $1.71M in Q4 2016. 1,526 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

R&F Capital Advisors reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
R&F Capital Advisors sold 23,851 Gilead Sciences shares in Q1 2017, an estimated $1.71M.
R&F Capital Advisors first reported a position in Gilead Sciences in Q4 2016 and held it in 1 quarter.
R&F Capital Advisors's Gilead Sciences position peaked at $1.71M in Q4 2016.
1,526 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.